Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis
Authors:
Open Access
- 11 October 2007
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 19 (4) , 503-510
Abstract
Strontium ranelate reduces the risk of fracture in post-menopausal osteoporotic women with prevalent fractures for whom quality of life is severely impaired. The SOTI study, which used the SF-36® questionnaire and disease-specific QUALIOST® module, demonstrated that treatment with strontium ranelate improved osteoporotic women’s quality of life compared with placebo. The Spinal Osteoporosis Therapeutic Intervention (SOTI) study demonstrated the effect of orally administered strontium ranelate versus placebo on the incidence of new vertebral fractures and compared impact on quality of life (QoL). QoL was assessed 6 monthly over 3 years using the QUALIOST® and SF-36® questionnaires in post-menopausal osteoporotic women with prevalent fracture taking strontium ranelate or placebo 2 g/day. A total of 1,240 women were included (strontium ranelate: n = 618 and placebo: n = 622). The QUALIOST® total score decreased in the strontium ranelate group, indicating preserved QoL compared with a deterioration in the placebo group (P = 0.016). Strontium ranelate patients had reduced QUALIOST® emotional and physical dimension scores (P = 0.019 and 0.032, respectively, versus placebo), indicating beneficial effects on emotional and physical functioning. There was a trend towards better SF-36® scores in the strontium ranelate group, although there were no significant between-group differences. More strontium ranelate patients (+ 31%) were free from back pain over 3 years versus placebo (P = 0.005), with a significant effect from the first year of treatment (P = 0.023). Strontium ranelate has beneficial effects on QoL in women with post-menopausal osteoporosis compared with placebo.Keywords
This publication has 20 references indexed in Scilit:
- The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal womenOsteoporosis International, 2005
- Reduced risk of back pain following teriparatide treatment: a meta-analysisOsteoporosis International, 2005
- The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 2004
- Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS)Journal of Bone and Mineral Research, 2002
- Patient-Reported Outcomes: The Example of Health-Related Quality of Life—a European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory ProcessDrug Information Journal, 2002
- Quality of life as outcome in the treatment of osteoporosis: The development of a questionnaire for quality of life by the European foundation for osteoporosisOsteoporosis International, 1997
- Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosisThe American Journal of Medicine, 1993
- Quality of life issues in women with vertebral fractures due to osteoporosisArthritis & Rheumatism, 1993
- Contribution of vertebral deformities to chronic back pain and disabilityJournal of Bone and Mineral Research, 1992
- Women with Osteoporosis: The Role of the Family and Service CommunityThe Gerontologist, 1988